Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

956 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer.
Vidula N, Niemierko A, Malvarosa G, Yuen M, Lennerz J, Iafrate AJ, Wander SA, Spring L, Juric D, Isakoff S, Younger J, Moy B, Ellisen LW, Bardia A. Vidula N, et al. Among authors: yuen m. Clin Cancer Res. 2021 Jun 15;27(12):3404-3413. doi: 10.1158/1078-0432.CCR-20-3444. Epub 2021 Jan 27. Clin Cancer Res. 2021. PMID: 33504549
FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer.
Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, Spring LM, Vidula N, Younger J, Peppercorn J, Yuen M, Malvarosa G, Sgroi D, Isakoff SJ, Moy B, Ellisen LW, Iafrate AJ, Arteaga CL, Bardia A. Drago JZ, et al. Among authors: yuen m. Clin Cancer Res. 2019 Nov 1;25(21):6443-6451. doi: 10.1158/1078-0432.CCR-19-0138. Epub 2019 Aug 1. Clin Cancer Res. 2019. PMID: 31371343 Free PMC article.
Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer.
Spring L, Niemierko A, Haddad S, Yuen M, Comander A, Reynolds K, Shin J, Bahn A, Brachtel E, Specht M, Smith BL, Taghian A, Jimenez R, Peppercorn J, Isakoff SJ, Moy B, Bardia A. Spring L, et al. Among authors: yuen m. Breast Cancer Res Treat. 2018 Dec;172(3):733-740. doi: 10.1007/s10549-018-4959-8. Epub 2018 Sep 15. Breast Cancer Res Treat. 2018. PMID: 30220055 Free PMC article.
Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer.
Medford AJ, Dubash TD, Juric D, Spring L, Niemierko A, Vidula N, Peppercorn J, Isakoff S, Reeves BA, LiCausi JA, Wesley B, Malvarosa G, Yuen M, Wittner BS, Lawrence MS, Iafrate AJ, Ellisen L, Moy B, Toner M, Maheswaran S, Haber DA, Bardia A. Medford AJ, et al. Among authors: yuen m. NPJ Precis Oncol. 2019 Jul 16;3:18. doi: 10.1038/s41698-019-0090-5. eCollection 2019. NPJ Precis Oncol. 2019. PMID: 31341951 Free PMC article.
Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience.
Wander SA, Han HS, Zangardi ML, Niemierko A, Mariotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Kambadakone A, Stein C, Lloyd MR, Yuen M, Spring LM, Juric D, Kuter I, Sanidas I, Moy B, Mulvey T, Vidula N, Dyson NJ, Ellisen LW, Isakoff S, Wagle N, Brufsky A, Kalinsky K, Ma CX, O'Shaughnessy J, Bardia A. Wander SA, et al. Among authors: yuen m. J Natl Compr Canc Netw. 2021 Mar 24:1-8. doi: 10.6004/jnccn.2020.7662. Online ahead of print. J Natl Compr Canc Netw. 2021. PMID: 33761455
Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B.
Hou J, Zhang W, Xie Q, Hua R, Tang H, Morano Amado LE, Yang SS, Peng CY, Su WW, Chuang WL, Kim DJ, Avihingsanon A, Kao JH, Leerapun A, Yuen MF, Asselah T, Liang X, Bo Q, Canducci F, Catanese MT, Chen E, Cheng C, Chughlay F, Das S, Glavini K, Guerreiro N, Huang Y, Kakrana P, Kazma R, Patil A, Pavlovic V, Surujbally B, Triyatni M, Upmanyu R, Wat C, Gane E; Piranga Study Group. Hou J, et al. Among authors: yuen mf. N Engl J Med. 2024 Dec 5;391(22):2098-2109. doi: 10.1056/NEJMoa2405485. N Engl J Med. 2024. PMID: 39774313 Clinical Trial.
Predictors of hepatic flares after nucleos(t)ide analogue cessation - Results of a global cohort study (RETRACT-B study).
Dongelmans EJ, Hirode G, Hansen BE, Chen CH, Su TH, Seto WK, Furquim d'Almeida A, van Hees S, Papatheodoridi M, Lens S, Wong GLH, Brakenhoff SM, Chien RN, Feld JJ, Chan HLY, Forns X, Papatheodoridis GV, Vanwolleghem T, Yuen MF, Hsu YC, Kao JH, Cornberg M, Sonneveld MJ, Jeng WJ, Janssen HLA; RETRACT-B study group. Dongelmans EJ, et al. Among authors: yuen mf. J Hepatol. 2024 Aug 31:S0168-8278(24)02493-0. doi: 10.1016/j.jhep.2024.08.015. Online ahead of print. J Hepatol. 2024. PMID: 39773379
956 results